TUDCA Dosage Guide: Evidence-Based Dosing Recommendations

TUDCA dosage as reported in the clinical literature varies widely with study design, and the dose used in a finished product is set by that product’s own formulation rather than by the raw material specification.

The TUDCA dosing recommendations below are derived from published clinical trials. No dose has been approved by the FDA for any indication; all doses described here are based on research protocols and conventional supplement use. This is not medical advice. Consult a licensed physician before taking TUDCA.

1. Standard Supplement Dose

The most common TUDCA supplement dose is 250-500 mg per day, typically taken in divided doses of 125-250 mg twice daily with meals. This dose range is used for general liver and metabolic support and is well-tolerated by most individuals. At 500 mg/day, the incidence of gastrointestinal side effects (primarily diarrhea) is approximately 5-10%. Capsule formulations in this range (250 mg, 500 mg per capsule) are the most widely available over-the-counter products.

For UDCA as a prescription drug (for reference only, since TUDCA and UDCA are not dose-equivalent), the FDA-approved doses are 13-15 mg/kg/day for PBC and 8-10 mg/kg/day for gallstone dissolution. UDCA doses are calculated per kilogram of body weight, whereas TUDCA dosing in the supplement context is typically a fixed daily amount.

2. Dosing for Liver Support

Liver support protocols use 250-500 mg/day, generally divided into two doses taken with breakfast and dinner. The clinical study that demonstrated ALT/AST/GGT reductions in chronic hepatitis patients used TUDCA in this dose range over a 3-month period. There is no evidence that doses above 500 mg/day provide additional liver benefit; the higher-dose protocols (1,000+ mg/day) have been studied exclusively in neurological and metabolic contexts.

3. Dosing in Clinical Trials

Higher TUDCA doses have been tested in specific patient populations under medical supervision:

The ALS trial's 1 g BID regimen is the highest dose studied in a published human trial exceeding 6 months. The 1,750 mg/day dose from the Kars metabolic study represents the highest single-dose total in a published trial, though it was only 4 weeks in duration.

4. How to Take TUDCA

• With meals: TUDCA should be taken with food. Bile acids are naturally released in response to dietary fat intake, and taking TUDCA with meals mimics this physiological timing, potentially improving tolerability and absorption.
• Divided dosing: For daily doses above 500 mg, splitting into 2-3 administrations reduces the peak intestinal concentration and lowers diarrhea risk.
• Timing with other medications: Separate TUDCA from bile acid sequestrants (cholestyramine, colesevelam) by at least 4 hours. Separate from aluminum-containing antacids by at least 2 hours. These agents bind TUDCA in the gut and prevent absorption.
• Dose escalation: When starting doses above 500 mg/day, an escalation from 250 mg/day to the target dose over 7-14 days allows assessment of gastrointestinal tolerance and reduces the likelihood of abrupt-onset diarrhea.

5. Overdose & Safety Ceiling

No formal maximum tolerated dose (MTD) has been established for TUDCA. The highest published dose is 2,000 mg/day for 54 weeks (ALS trial), at which no dose-limiting toxicities were observed. In the absence of an established MTD, there is no evidence-based rationale for exceeding 2,000 mg/day. At doses above 1,500 mg/day, diarrhea becomes the rate-limiting side effect for most individuals.

In the event of acute overdose (well above recommended doses), the expected toxicity profile would mirror therapeutic side effects at higher intensity: severe diarrhea with risk of dehydration and electrolyte imbalance. Treatment is supportive (rehydration, electrolyte replacement). There is no specific antidote for TUDCA.

6. Doctor Consultation Advisory

TUDCA is not a food or a vitamin. It is a bioactive bile acid with pharmacological effects. The following scenarios require medical consultation before starting TUDCA:

• Any pre-existing liver, gallbladder, pancreas, or biliary tract condition
• Current use of prescription medications (especially CYP3A4 substrates, anticoagulants, immunosuppressants)
• Pregnancy, planned pregnancy, or breastfeeding
• Any chronic medical condition requiring ongoing treatment
• Planned doses above 500 mg/day
• Any adverse symptom that develops during TUDCA use and persists beyond 72 hours

Physicians managing patients who inquire about TUDCA should reference the published clinical literature directly, as TUDCA is not listed in standard pharmaceutical references with approved dosing monographs.

Related Articles

References

1. Elia AE, Lalli S, Monsurro MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45-52.
2. Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899-1905.
3. Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med. 2014;3(3):58-69.

7. Frequently Asked Questions